

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: herewith Oct. 1999	Group: Unknown 1624

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
BC	2,086,585	07/01/1937	Taub, et al.	260	127	
BC	2,087,132	07/13/1937	Taub, et al.	260	127	
BC	2,108,765	02/15/1938	Domagk	167	30	
BC	2,209,383	07/30/1940	Bock	8	116	
BC	2,439,969	04/20/1948	Fourneau	260	338	
BC	2,445,393	07/20/1948	Fourneau	260	338	
BC	2,513,747	07/04/1950	Sallman, et al.	260	338	
BC	2,606,909	08/12/1952	Blicke	260	338	
BC	2,689,790	09/21/1954	Mowry, et al.	71	2.7	
BC	2,950,253	08/23/1960	Kling, et al.	252	152	
BC	3,054,678	09/18/1962	Michener, et al.	99	150	
BC	3,694,473	09/26/1972	Eibl, et al.	260	403	
BC	4,093,714	06/06/1978	Tolman, et al.	424	180	
BC	4,096,278	06/20/1978	Queuille	424	329	
BC	4,119,714	10/10/1978	Kny, et al.	424	199	
BC	4,159,988	07/03/1979	Eibl, et al.	260	340	
BC	4,235,877	11/25/1980	Fullerton, W.W.	424	89	06/27/79
BC	4,329,302	05/11/1982	Hanahan, et al.	260	925	
BC	4,426,525	01/17/1984	Hozumi, et al.	546	22	
BC	4,444,766	04/24/1984	Bosies, et al.	425	211	
BC	4,471,113	09/11/1984	MacCoss	536	29	
BC	4,540,521	09/10/1985	Garst, et al.	260	459	
BC	4,619,917	10/28/1986	Lee, et al.	514	77	
BC	4,661,509	04/27/1987	Gordon, et al.	514	397	
BC	4,816,450	03/28/1989	Bell, et al.	514	25	
BC	4,826,823	05/02/1989	Cook, et al.	514	46	
BC	4,835,263	05/30/1989	Nguyen, et al.	536	27	
BC	4,837,023	06/06/1989	Eibl	424	439	
BC	4,841,039	06/20/1989	Chu, et al.	536	29	
BC	4,880,782	11/14/1989	Eckstein, et al.	514	45	
BC	5,034,394	07/23/1991	Daluge, S.M.	514	261	12/22/89
BC	5,138,045	08/11/1992	Cook, P.D., et al.	536	27	07/27/90

JC625 U.S. PTO
 09/412539
 10/05/99

Examiner <i>Brenda Coleman</i>	Date Considered <i>April 18, 2000</i>
-----------------------------------	--

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: herewith Oct. 1999	Group: Unknown 1624

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
-----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

	**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	BC	0094586	11/23/1983	European	---	---		
	BC	0109255	05/23/1984	European	---	---		
	BC	0142333	06/19/1985	European	---	---		
	BC	0145303	06/26/1985	European	---	---		
	BC	0146258	05/22/1985	European	---	---		
***	BC	0252310	06/06/1987	European	---	---		
	BC	0310109	04/05/1989	European	---	---		
	BC	0335396	02/23/1989	European	---	---		
	BC	0348859	01/03/1990	European	---	---		
***	BC	0416401	08/25/1990	European	---	---		
	BC	0434450	12/21/1990	European	---	---		
	BC	0506704	07/11/1991	European	---	---		
	BC	0632048	06/23/1994	European	---	---		
***	BC	1029319	01/31/1989	Japan	---	---		
***	BC	1561630	03/28/1969	France	---	---		
***	BC	3726945A1	10/04/1989	Germany	---	---		
***	BC	3934820A1	04/25/1991	Germany	C07F	9/09		
	BC	4010228A1	10/02/1991	Germany	A61K	31/605		
✓	BC	42-13841	08/05/1967	Japan	---	---		
✓	BC	49-100224	09/21/1974	Japan	---	---		
	BC	90/05736	03/13/1991	PCT	---	---		
	BC	90/15601	12/27/1990	PCT	---	---		
***	BC	91/05558	05/02/1991	PCT	---	---		
	BC	91/09602	07/11/1991	PCT	---	---		
	BC	91/18914	12/12/1991	PCT	---	---		
***	BC	92/03462	03/05/1992	PCT	---	---		
	BC	92/06192	04/16/1992	PCT	C12N	15/11		
	BC	93/08807	05/13/1993	PCT	---	---		
***	BC	93/16091	08/19/1993	PCT	---	---		
***	BC	93/16092	08/19/1993	PCT	---	---		
	BC	93/17020	09/02/1993	PCT	---	---		
✓	BC	93/21191	10/28/1993	PCT	C07F	9/10		

Examiner <i>Brenda Coleman</i>	Date Considered <i>April 18, 2000</i>
-----------------------------------	--

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*** structures only

Form 1449*	Atty. Docket No.: <u>00443-1703</u>	<u>09/412,539</u>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: <u>August 7, 1999</u> August 7, 1999 ^{Oct. 1999}	Group: <u>Unknown</u> ¹⁶²⁴

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
-----------------------	-----------------	------	------	-------	----------	-------------------------------

OTHER DOCUMENTS

**Examiner Initial (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Aggarwal, "Synthesis and Biological Evaluation of Prodrugs of Zidovudine", <u>J. Med. Chem.</u> , 33, 1505-10 (1990),
BC	Boldanova, et al., "Protective effect of Phosphatidylcholine-containing Liposomes in Experimental Toxic Hepatitis", <u>Vopr. Med. Khim.</u> , 32, no. 3 (1986) <u>Chemical Abstracts</u> , 105, p. 67, Abstract No. 35587k (1986),
✓ BC	Bosies, et al., "Chemical Abstracts", <u>115CA:72142p</u> 1991,
BC	Chen, "Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents", <u>Abstract American Assoc. of Pharmaceutical Scientists</u> , Orlando Fl., (1993),
BC	Crumpton, "Novel Lipid Analogs with Cytostatic and Cytocidal Activity", <u>Submitted to Anticancer Res.</u> , Vol. 8, No. 6, pp. 1361-1366 (Nov. - Dec. 1988),
BC	Daniel, "Alkyl-Linked Diglycerides Inhibit Protein Kinase C Activation by Diacylglycerols", <u>Biochemical & Biophysical Res. Comm.</u> , 151, 291-97 (Feb. 29, 1988),
BC	Diétzfelbinger, "Cytotoxic and Purging Effects of ET-18-OCH ₃ in Human Malignant Lymphoid Cell Lines in Vitro", <u>Abstract 2472, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990),
BC	Fields, "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor", <u>Nature</u> , 333, 278-80 (19 May 1988),
BC	Harada, "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay", <u>Science</u> , 229, 563- 566 ⁵⁶⁶ (9 Aug. 1985),
BC	Himmelmann, "Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro", <u>Abstract 2448, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990),

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: August 7, 1995 ^{Oct. 1999} herewith	Group: Unknown ¹⁶³⁴

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

BC	Hsu, L., et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides", <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, (1992),
BC	Kasnar, B., et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'-Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents", <u>Nucleosides & Nucleotides</u> , 13(1-3), pp. 459-479, (1994),
BC	Korba, "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication", <u>Antiviral Res.</u> , 19, 55-70 (1992),
BC	Krugner-higby, L., et al., "Membrane-Interactive Phospholipids Inhibit HIV Type 1-Induced Cell Fusion and Surface gp160/gp120 Binding to Monoclonal Antibody", <u>AIDS Research and Human Retroviruses</u> , 11, 705-712, (1995)
BC	Krugner-higby, et al., "Novel Membrane Interactive Ether Lipid Analogs Inhibit HIV-1 Glycoprotein Interaction with CD4+ Cells", <u>Abstract from 32nd Interscience Conf on Antimicrobial Agents and Chemotherapy</u> , Anaheim, 164, (11-14 Oct. 1992),
BC	Kucera, L.S., et al., "Activity of Triciribine and Triciribine-5'-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2", <u>Aids Research and Human Retroviruses</u> , Vol. 9, No. 4, pp. 307-314, (1993),
BC	Kucera, "Effect of Membrane-Active Ether Lipid (EL) Analogues on Human Immunodeficiency Virus Production Measured by Plaque Assay", <u>Annals of the New York Acad. of Sciences</u> , 546-548 (26 Dec. 1990),
BC	Kucera, "Inhibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Lipid Analogs", <u>International Conference on AIDS</u> , Abstract No. W.C.O.21, June 4-9, 1989, p. 528.,
BC	Kucera, "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) by Novel Membrane Interactive Ether Lipids", <u>Abstract No. 2470, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990),

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00 443 - 1743	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: herewith Oct. 1999	Group: Unknown 1624

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

BC	Kucera, L., et al., "Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Medicated Cell Fusion by Synthetic Phospholipid Analogs", <u>Antiviral Research</u> (1995),
BC	Kucera, "Investigations on Membrane Active Ether Lipid Analogs that Alter Functional Expression of HIV-1 Induces Glycoproteins and Inhibit Pathogenesis", <u>Abstract, Innovations in Therapy of Human Viral Diseases, Symposium, Research Triangle Park, 16, (6-9 Dec. 1992),</u>
BC	Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity", <u>Abstract, ICAAC Orlando, (1994),</u>
BC	Kucera, "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation", <u>AIDS Research and Human Retroviruses, 6, 491-501 (1990),</u>
	Kuman, et al., "Chemical Abstract", <u>117CA 124476; (1992)</u>
BC	Kumar, R., et al., "Equal Inhibition of HIV Replication by Stereoisomers of Phosphatidyl-Azidothymidine - Lack of Stereospecificity of Lysosomal Phospholipase A1", <u>J. Biol. Chem., 267, 20288-20292, (1992)</u>
BC	Marasco, Jr., "The Synthesis and Biological Activity of Novel Alkylglycerol Derivatives as Inhibitors of Protein Kinase C Activity, Neoplastic Cell Growth and HIV-1 Infectivity", <u>Dissertation for Ph.D., Univ. of No. Carolina, Chapel Hill 1990,</u>
BC	Marasco, et al., "Synthesis and Biological Activity of Novel Quaternary Ammonium Derivatives of Alkylglycerols as Potent Inhibitors of Protein Kinase C", <u>Jour. of Med. Chem., 33, No. 3, pp. 985-992 (March 1990),</u>
BC	Marasco, "The Synthesis, Biological Evaluation, and Structure Activity of Amido Phosphocholines and Related Analogs as Anti-HIV-1 Agents", <u>6th Conf. on AIDS, San Francisco, Abstract, (20-24 June 1990),</u>
BC	Marasco, et al., "The Synthesis and Biological Testing of Alkyl Glycerols as Potential Inhibitors of Protein Kinase C", <u>American Assoc. of Pharmaceutical Scientists Abstract, Orlando Fl., (1993),</u>

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
-----------------------------------	--

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: here with Oct. 1999	Group: Unknown 1624

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

BC	Marx, "Synthesis and Evaluation of Neoplastic Cell Growth Inhibition of 1-N-Alkylamide Analogues of Glycero-3-phosphocholine", <u>J. Med. Chem.</u> , 31, 858-863 (3-28-88),
BC	Meyer, K.L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents", <u>J. Med. Chem.</u> , 34, 1377-1383, (1991)
BC	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids", <u>AAPS Meeting, Atlanta Abstract N. MN-510</u> , p. S-41, (22-25 Oct. 1989),
	Miller, R.H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses", <u>Proc. Natl. Acad. Sci. USA</u>, 83, pp. 2531-2535, (1986)
BC	Mitsuya, "Strategies for Antiviral Therapy in AIDS", <u>Nature</u> , 325, 773-78 (1987),
BC	Modest, "Antineoplastic and Antiviral Properties of Ether Lipid Analogs", <u>15th Intl Cancer Congress, Abstract (16-22 Aug 1990)</u> ,
BC	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs", <u>Abstract 2471, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 Abstract 2471 (March 1990),
BC	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia", <u>Proceedings of the American Association for Cancer Research; Preclinical Pharmacology Experimental Therapeutics</u> , Vol. 31, pp. 416, Abstract 2467, (March 1990),
BC	Modest, "Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs", <u>The Pharmacological Effect of Lipids. III: The Role of Lipids in Carcinogenesis and Therapy</u> , (IN PRESS), pp. 330-337 (1989),
BC	Morrey, "Effects of Zidovudine on Friend Virus Complex Infection in Frv-3r/s Genotype-Containing Mice Used as a Model for HIV Infection", <u>J. of Acquired Immune Deficiency Syndromes</u> , 3, 500-10 (1990),

Examiner Brenda Coleman	Date Considered April 18, 2000
----------------------------	-----------------------------------

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: herewith Oct. 1999	Group: 1624

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

BC	Morris-natschke, "Synthesis of Sulfur Analogues of Alkyl Lysophospholipid and Neoplastic Cell Growth Inhibitory Properties", <u>J. of Med. Chem.</u> , 29, 2114-17 (1986),
BC	Nara, "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human Immunodeficiency Virus Neutralizing Antibody", <u>Aids Res. and Human Retroviruses</u> , 3, 283-302 (1987),
BC	Noseda, "In Vitro Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive Agents Against Human Tumor Cells", <u>Journal of Cancer Research</u> , 48, 1788-1791 (April 1988),
BC	Noseda, "Neoplastic Cell Inhibition with New Ether Lipid Analogs", <u>Lipids</u> , 22, 878-883 (Nov. 1987),
BC	Ostertag, "Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus", <u>Proc. Nat. Acad. Sci. USA</u> , 71, 4980-85 (Dec. 1974),
	Pacheco, "Mechanisms of Toxicity of Hepsulfam in Human Tumor Cell Lines", Abstract 2446, Proceedings of the American Assoc. for Cancer Res., 31, 416 (March 1990),
BC	Piantadosi, "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity", <u>J. Med. Chem.</u> , 34, 1408-14 (1991),
	Pidgeon, et al., "Chemical Abstract", 120CA69591g, (1994)
BC	Sarin, et al., "Effects of a Novel Compound (AL 721) on HTLV-III Infectivity in Vitro", <u>New England J. of Med.</u> , 313, 1289-90 (Nov. 14, 1985),
	Seclero, et al., "Chemical Abstract", 117CA124476p, (1992)
	Small, "Characterization of Cells Sensitive and Resistant to BT 18 OCH3", Abstract 2447, Proceedings of the American Assoc. for Cancer Res., 31, 416 (March 1990),
	Sumamoto, et al., "Chemical Abstract" 117CA68365n, (1992)

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: <u>00443-1703</u>	<u>09/412,539</u>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: <u>herewith Oct. 1999</u>	Group: <u>1634</u> Unknown

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

<u>BC</u>	Swayze, E.E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the Tibo Derivative R82150, With Activity Against Human Immunodeficiency Virus", <u>Bioorganic & Medical Chemistry Letters</u> , Vol. 3, No. 4, pp. 543-546, (1993),
<u>BC</u>	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion", <u>Abstracts of the 2nd National Conference on Human Retroviruses, Session 18, (1995)</u> ,
<u>BC</u>	Tiollais, P., et al., "Hepatitis B. Virus", <u>Scientific American</u> , 116-123, (April 1992)
<u>BC</u>	Van Wijk, G.M., et al., "Spontaneous and Protein-Mediated Intermembrance Transfer of the Antiretroviral Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceride", <u>Biochem</u> , 31, 5912-5917, (1992)
<u>BC</u>	Yanagawa, "Spontaneous Formation of Superhelical Strands", <u>J. Am. Chem. Soc.</u> , 111, 4567-70 (1989),
<u>BC</u>	Yarchoan, "Therapeutic Strategies in the Treatment of AIDS", <u>Annual Reports in Medicinal Chemistry</u> , 253-263 (1988),

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.